[ARNA] Arena Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 396.16 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.53 Change: 0.06 (4.08%)
Ext. hours: Change: 0 (0%)

chart ARNA

Refresh chart

Strongest Trends Summary For ARNA

ARNA is in the long-term up 213% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company?s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug

Fundamental Ratios
Shares Outstanding243.04 M EPS0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.26% Sales Growth - Q/Q33.35% P/E65.5
P/E To EPS Growth P/S9.34 P/BV3.07 Price/Cash Per Share
Price/Free Cash Flow-3.59 ROA-16.44% ROE-46.18% ROI
Current Ratio3.61 Quick Ratio3.46 Long Term Debt/Equity0.35 Debt Ratio0.58
Gross Margin76.36% Operating Margin-243.99% Net Profit Margin-140.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities101.41 M Cash From Investing Activities-1.07 M Cash From Operating Activities-23.02 M Gross Profit8.66 M
Net Profit-24.3 M Operating Profit-21.74 M Total Assets362.29 M Total Current Assets268.62 M
Total Current Liabilities74.36 M Total Debt70.17 M Total Liabilities233.35 M Total Revenue12.26 M
Technical Data
High 52 week49.63 Low 52 week30.89 Last close43.58 Last change-0.37%
RSI72.62 Average true range2.02 Beta1.02 Volume2.08 M
Simple moving average 20 days7.91% Simple moving average 50 days9.66% Simple moving average 200 days6.16%
Performance Data
Performance Week-0.91% Performance Month6.06% Performance Quart10.83% Performance Half-2.22%
Performance Year28.63% Performance Year-to-date11.89% Volatility daily3.16% Volatility weekly7.07%
Volatility monthly14.48% Volatility yearly50.18% Relative Volume420.94% Average Volume624.51 K
New High New Low


2019-03-18 15:36:06 | These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts

2019-03-08 08:30:00 | Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation

2019-02-28 10:16:03 | United Therapeutics UTHR Q4 Earnings & Sales Beat Estimates

2019-02-27 16:09:45 | Edited Transcript of ARNA earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-27 08:25:01 | Arena Pharmaceuticals ARNA Beats on Q4 Earnings & Revenues

2019-02-26 20:52:36 | Arena Pharmaceuticals Inc ARNA Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:01:00 | Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

2019-02-25 15:25:04 | 5 Clinical Stage Biotech Stocks to Buy

2019-02-21 08:30:00 | Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

2019-02-20 16:01:00 | Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26

2019-02-15 09:05:51 | Top 3 Marijuana Stocks on the NASDAQ

2019-02-07 16:30:00 | Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress

2019-01-30 10:23:41 | Is Arena Pharmaceuticals, Inc. NASDAQ:ARNA A Financially Strong Company?

2019-01-30 07:55:00 | Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-25 07:38:05 | The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

2019-01-24 20:00:00 | Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

2019-01-24 20:00:00 | United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

2019-01-21 10:53:42 | Top Marijuana Stocks on the NASDAQ

2019-01-07 08:30:00 | Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis

2018-12-19 08:30:00 | Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10

2018-12-17 08:30:00 | Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors

2018-12-13 22:05:54 | Is Arena Pharmaceuticals, Inc. ARNA A Good Stock To Buy?

2018-12-13 06:55:00 | Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings

2018-12-10 12:09:33 | What Did Arena Pharmaceuticals Inc’s NASDAQ:ARNA CEO Take Home Last Year?

2018-12-06 06:50:00 | Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics

2018-11-27 07:35:00 | Research Report Identifies Cheniere Energy Partners, LP, Arena Pharmaceuticals, Geron, Keysight Technologies, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Casella Waste with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-11-27 05:00:00 | Analysts: Why United Therapeutics has had a streak of licensing deals

2018-11-26 11:33:36 | A Look at Amarin Corporation’s Stock Performance Year-to-Date

2018-11-26 08:30:00 | Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs

2018-11-23 12:58:05 | 2 New Small Cap ETFs on the Block

2018-11-21 11:30:00 | Opioid Alternatives Could Make Investors Major Gains

2018-11-21 11:21:04 | Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal

2018-11-20 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

2018-11-17 08:31:00 | My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy

2018-11-16 09:11:02 | Arena ARNA Out-Licenses Rights to PAH Drug, Stock Up 22%

2018-11-16 07:00:00 | Today’s Research Reports on Stocks to Watch: Arena Pharmaceuticals and Sonoma Pharmaceuticals

2018-11-15 16:30:00 | Why Arena Pharmaceuticals, Smart & Final Stores, and Tilray Jumped Today

2018-11-15 15:38:46 | Stocks on the move: JP Morgan shares increase as Walmart beat estimates but shy on revenue

2018-11-15 12:33:22 | Why Arena Pharmaceuticals Stock Is Soaring Today

2018-11-15 11:05:00 | Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today

2018-11-15 09:58:00 | 4 Stocks To Watch As Investors Dump Tech; Head To Healthcare

2018-11-15 07:33:03 | United Therapeutics to develop, sell Arena Pharma's hypertension treatment

2018-11-15 07:00:00 | Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

2018-11-13 08:30:00 | Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions

2018-11-09 10:22:03 | Arena Pharmaceuticals ARNA Beats on Q3 Earnings and Sales

2018-11-08 13:37:16 | Edited Transcript of ARNA earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 16:01:00 | Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results

2018-11-07 14:58:00 | Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

2018-10-31 08:30:00 | Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7

2018-10-30 10:33:02 | Analysts Estimate Arena Pharmaceuticals ARNA to Report a Decline in Earnings: What to Look Out for